ArticleInternational journal of clinical and experimental medicine2015
Interferon-γ polymorphism and hepatocellular carcinoma susceptibility: a meta analysis.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Predictive Value of Interferon γ Receptor Gene Polymorphisms for Hepatocellular Carcinoma Susceptibility.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms.World journal of gastroenterology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterferon-gamma (IFN-γ) was first defined as an antiviral agent with potent antitumor effects in 1957 and this is supported by much subsequent research. IFN-γ rs2430561 polymorphism was found to increase IFN-γ production involved in the regulation of immune system. Previous studies of rs2430561 genotypes and hepatocellular carcinoma (HCC) susceptibility have produced inconsistent results. We thus summarized all epidemiologic and molecular data and carried out a meta-analysis to evaluate the effects of this functional polymorphism on HCC incidence.
methodsHuman hospital- or population-based studies were identified by searching multiple databases (BIOSIS, Embase, PubMed, Web of Science, Chinese Biomedical Literature database). Six studies were selected for the meta-analysis. Crude ORs was calculated assuming the allele, homozygote, heterozygote, dominant and recessive model. The stability and reliability of the combined results were examined by using sensitivity analysis and publication bias tests.
resultsMeta-analysis under the allele model showed that the T allele compared with the A allele showed a moderately but nonsignificantly increased risk of HCC (OR = 1.12, 95% CI = 0.92-1.35). Analyses under the remaining models revealed no evidence of a significant association. In subgroup analysis by infection type, summary ORs suggested no significantly elevated risk of HBV-infected HCC in relation to the allele or genotypes of rs2430561 polymorphism. The combined results were reliable according to sensitivity analysis and publication bias tests.
conclusionWe found no strong evidence supporting a statistically significant association between IFN-γ rs2430561 polymorphism and HCC susceptibility.
Indexed as
Identifiers
26131150PMC4483975W2415463923What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.